Anti-Aspergillus fumigatus IgG in patients with bronchiectasis and its relationship with clinical outcome.
Author:
Trápaga MR, Poester VR, Sanchotene KO, Melo AM, Benelli JL, Basso RP, Klafke GB, Ramos DF, Veríssimo C, Sabino R, Stevens DA, Xavier MO.
Date: 24 November 2022
Abstract:
Aspergillosis is a mycosis, most commonly affecting the airways. This mycosis can worsen the clinical condition of patients with concurrent lung diseases. We assayed for the presence of serum anti-A. fumigatus IgG in bronchiectasis patients from a tertiary hospital in south Brazil and evaluated the relationship with clinical outcome. Thirty-one patients with bronchiectasis, without cystic fibrosis, were included. Clinical and epidemiological data were collected from all participants. Positive serological tests were detected in 13% (4/31) of the patients. The mortality rate for the year following the assay was, in the seropositive group, 75% (3/4), whereas in the seronegative group, 15% (4/27). An illustrative case is also shown and discussed. Our study highlights the diagnostic challenge and the possible impact of Aspergillus infection on these patients, indicating the necessity of more and larger investigations in the field.
Keywords: Aspergillosis; Aspergillus IgG; ELISA; Fungal disease; Immunodiffusion.
Download the full article (Disclaimer)
This manuscript library of ~16,000 articles (1729-2024) related to Aspergillus and aspergillosis is intended for individual study only, and is provided as contribution to global understanding of the topic. Please refer to the publisher’s guidance about any other usage.